首页> 外文期刊>Science translational medicine >Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
【24h】

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

机译:复发的GNAS突变定义了胰腺囊肿发展的意外途径。

获取原文
获取原文并翻译 | 示例
           

摘要

More than 2% of the adult U.S. population harbors a pancreatic cyst. These often pose a difficult management problem because conventional criteria cannot always distinguish cysts with malignant potential from those that are innocuous. One of the most common cystic neoplasms of the pancreas, and a bona fide precursor to invasive adenocarcinoma, is called intraductal papillary mucinous neoplasm (IPMN). To help reveal the pathogenesis of these lesions, we purified the DNA from IPMN cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. In addition to the expected KRAS mutations, we identified recurrent mutations at codon 201 of GNAS. A larger number (113) of additional IPMNs were then analyzed to determine the prevalence of KRAS and GNAS mutations. In total, we found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. In addition to defining a new pathway for pancreatic neoplasia, these data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.
机译:超过2%的美国成年人口患有胰腺囊肿。由于常规标准不能总是将具有恶性潜能的囊肿与无害的囊肿区分开来,因此这些通常会带来困难的管理问题。胰腺最常见的囊性肿瘤之一,是浸润性腺癌的真正前体,被称为导管内乳头状黏液性肿瘤(IPMN)。为了帮助揭示这些病变的发病机理,我们从19例患者的IPMN囊液中纯化了DNA,并搜索了人类癌症中通常会改变的169个基因的突变。除了预期的KRAS突变外,我们还确定了GNAS 201密码子处的重复突变。然后分析了更多(113)的其他IPMN,以确定KRAS和GNAS突变的发生率。总的来说,我们发现66%的IPMN中存在GNAS突变,而96%的人可以识别出KRAS或GNAS突变。在八种情况下,我们可以调查与含有GNAS突变的IPMN联合发展的浸润性腺癌。在这八种病例中的七种中,在侵入性病变中还发现了IPMN中存在的GNAS突变。在其他类型的胰腺囊性肿瘤或与IPMN不相关的浸润性腺癌中未发现GNAS突变。这些数据除了为胰腺肿瘤定义新的途径外,还表明GNAS突变可以为囊性胰腺病变患者的诊断和治疗提供依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号